We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > KEYTRUDA®

News List

NGM Bio Clinical Trial Collaboration with Merck on NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination KEYTRUDA® AmericanPharmaceuticalReview
December 07, 2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and..
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo americanpharmaceuticalreview
May 23, 2019
OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...